-

Lucence Launches DeepMARK™ for Profiling of SARS-CoV-2 Subgenomic RNA

NGS assay for profiling SARS-CoV-2 genomic and subgenomic RNA in clinical specimens has compelling use cases for rapid public health response, research, and vaccine development

original (Photo: Business Wire)

(Photo: Business Wire)

SINGAPORE--(BUSINESS WIRE)--Molecular diagnostics company Lucence today announced the availability of the world’s first assay kit to directly profile SARS-CoV-2 subgenomic RNA (sgRNA), a marker of active viral replication1, from clinical samples. DeepMARK™ utilizes Lucence’s proprietary ultrasensitive next-generation sequencing (NGS) technology, AmpliMARK™, to concurrently detect and analyze the genome and transcriptome of SARS-CoV-2.

Pinpointing sources of unlinked SARS-CoV-2 cases supports rapid public health response. Using high-quality genetic fingerprinting, DeepMARK™ can enable rapid community case tracing by identifying transmission paths, clusters, and viral contagiousness. DeepMARK™’s increased sensitivity also allows for asymptomatic and recovering cases to be more thoroughly evaluated for contagiousness.

For researchers studying contagiousness, SARS-CoV-2 sgRNA is a recognized marker of active viral replication linked with contagiousness2 and offers several advantages. While viral culture is the gold standard, it is slow, expensive, and requires a biosafety level 3 (BSL3) laboratory, requirements prohibitive for the vast majority of samples. Using DeepMARK™, clinical samples can be safely and efficiently profiled using a simple workflow.

SgRNA as a marker of viral replication is also a well-recognized efficacy measurement in SARS-CoV-2 vaccine development3. Thus, comprehensive sgRNA profiling by DeepMARK™ could facilitate more efficient vaccine discovery.

“Genetic fingerprinting enables quicker and deeper analysis of viral spread. This tool has enhanced our capacity to understand SARS-CoV-2 precisely and contributes to the ongoing fight against COVID-19.” said A/Prof Hsu Li Yang, Vice Dean, Global Health, Saw Swee Hock School of Public Health, National University of Singapore.

DeepMARK™ is part of Lucence’s suite of SARS-CoV-2 molecular diagnostics. Lucence also makes the SAFER™ Sample Kit, a saliva stabilization kit with reported 36% higher sensitivity for detecting COVID-19 compared to nasopharyngeal swabbing4.

About DeepMARK™

DeepMARK™ is a next-generation sequencing (NGS) assay kit for the qualitative analysis of SARS-CoV-2 RNA. For Investigational Use Only. The performance characteristics of this product have not been established.

About Lucence

Lucence is a molecular diagnostics company that makes state-of-the-art, highly sensitive tests for disease detection and treatment selection. Headquartered in Singapore and California, Lucence’s services are delivered worldwide through an accredited central laboratory. For more information, contact enquiry@lucence.com or visit www.lucence.com/deepmark.

References

1. https://www.nature.com/articles/s41586-020-2196-x

2. https://wwwnc.cdc.gov/eid/article/26/11/20-3219_article

3. https://www.nejm.org/doi/full/10.1056/NEJMoa2024671

4. https://www.medrxiv.org/content/10.1101/2020.08.13.20173807v1

Contacts

Gabriel Yap
media@lucence.com

Industry:

Lucence

Release Versions
EnglishGermanChinese Simplified

Contacts

Gabriel Yap
media@lucence.com

More News From Lucence

Lucence and Yemaachi Launch the AMBER Study to Detect and Characterize Genomic Alterations in Breast Cancer in Women in Africa and Expand Liquid Biopsy Access

PALO ALTO, Calif. & ACCRA, Ghana--(BUSINESS WIRE)--Lucence, a precision oncology company using liquid biopsy to bring clarity to cancer care, and Yemaachi Biotech, a cancer research company based in Accra, Ghana, announced today that they are collaborating on a study to better characterize and understand the genomics of breast cancer in women of African descent. The study– Liquid Biopsy for Detection of Actionable Genomic Mutations in Women of African Descent with Advanced Breast Cancer, also k...

Lucence Presents Data at ESMO 2021 Showing Liquid Biopsy Detects Actionable Genomic Alterations in Bladder Cancer Patients Undergoing Immunotherapy

PALO ALTO, Calif.--(BUSINESS WIRE)--Precision oncology company Lucence, in collaboration with researchers at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, is sharing data highlighting the capabilities of its amplicon-based liquid biopsy technology to detect and characterize genomic alterations in ctDNA in patients with late-stage bladder cancer undergoing immunotherapy. The data will be presented as part of a virtual poster presentation at the European Society for Medical Oncol...

Lucence Presents Real-World Evidence on Applications of Liquid Biopsy at 2021 ASCO, Announces Formation of Medical Advisory Board

PALO ALTO, Calif.--(BUSINESS WIRE)--As part of the 2021 ASCO Annual Meeting, precision oncology company Lucence is sharing real-world data supporting clinical applications of its amplicon-based liquid biopsy assay. The data will be presented in on-demand virtual poster sessions, available beginning June 4 at 9 AM EDT. Lucence is also announcing the formation of a medical advisory board in the United States. Lucence’s Medical Advisory Board will be tasked with providing strategic, patient-center...
Back to Newsroom